The press release highlights that there are currently no available disease-modifying treatments for Fuchs endothelial corneal dystrophy, emphasizing the seriousness and lack of options for ...

today announced that it will present an update on the progress of its DT-168 program for Fuchs endothelial corneal dystrophy (FECD) at Eyecelerator @ Park City 2025 on Friday, May 2, 2025 ...

When cataract surgery leads to complications, patients arrive at the retina surgeon’s office scared and uncertain.As specialists, our role is not to dwell on how we got here but to chart the path ...

A major therapeutic and commercial opportunity awaits TTHX1114 in age-related corneal diseases. In the US and Europe, approximately 600,000 people have Fuchs dystrophy, the most common type of CED ...

today announced that it will present an update on the progress of its DT-168 program for Fuchs endothelial corneal dystrophy (FECD) at Eyecelerator @ Park City 2025 on Friday, May 2, 2025, at 1:30 p.m ...